Astaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. It is classified as a xanthophyll but it is a carotenoid with no vitamin A activity. It is found in the majority of aquatic organisms with red pigment. Astaxanthin has shown to mediate anti-oxidant and anti-inflammatory actions. It may be found in fish feed or some animal food as a color additive.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | Apixaban may increase the anticoagulant activities of Astaxanthin. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of Astaxanthin. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Astaxanthin. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when Astaxanthin is combined with Deferasirox. |
| Ursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Hyodeoxycholic Acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Astaxanthin. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Astaxanthin. |
| Obinutuzumab | The risk or severity of bleeding and hemorrhage can be increased when Astaxanthin is combined with Obinutuzumab. |
| Rivaroxaban | Astaxanthin may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when Astaxanthin is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of Astaxanthin. |
| Tipranavir | The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Astaxanthin. |
| Urokinase | Urokinase may increase the anticoagulant activities of Astaxanthin. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Astaxanthin. |
| Aprotinin | The therapeutic efficacy of Astaxanthin can be decreased when used in combination with Aprotinin. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of Astaxanthin. |
| Ifosfamide | The risk or severity of bleeding can be increased when Ifosfamide is combined with Astaxanthin. |
| Quinine | The therapeutic efficacy of Astaxanthin can be increased when used in combination with Quinine. |
| Quinidine | The therapeutic efficacy of Astaxanthin can be increased when used in combination with Quinidine. |
| Tamoxifen | The risk or severity of bleeding can be increased when Tamoxifen is combined with Astaxanthin. |
| Toremifene | The risk or severity of bleeding can be increased when Toremifene is combined with Astaxanthin. |
| Pentoxifylline | The therapeutic efficacy of Astaxanthin can be increased when used in combination with Pentoxifylline. |
| Pentosan polysulfate | Pentosan polysulfate may increase the anticoagulant activities of Astaxanthin. |
| Levocarnitine | The therapeutic efficacy of Astaxanthin can be increased when used in combination with Levocarnitine. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the anticoagulant activities of Astaxanthin. |
| Chlorotrianisene | Chlorotrianisene may decrease the anticoagulant activities of Astaxanthin. |
| Conjugated estrogens | Conjugated estrogens may decrease the anticoagulant activities of Astaxanthin. |
| Mestranol | The risk or severity of adverse effects can be increased when Mestranol is combined with Astaxanthin. |
| Estrone sulfate | Estrone sulfate may decrease the anticoagulant activities of Astaxanthin. |
| Quinestrol | Quinestrol may decrease the anticoagulant activities of Astaxanthin. |
| Hexestrol | Hexestrol may decrease the anticoagulant activities of Astaxanthin. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Astaxanthin. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Astaxanthin. |
| Polyestradiol phosphate | Polyestradiol phosphate may decrease the anticoagulant activities of Astaxanthin. |
| Esterified estrogens | Esterified estrogens may decrease the anticoagulant activities of Astaxanthin. |
| Zeranol | Zeranol may decrease the anticoagulant activities of Astaxanthin. |
| Equol | Equol may decrease the anticoagulant activities of Astaxanthin. |
| Methallenestril | Methallenestril may decrease the anticoagulant activities of Astaxanthin. |
| Epimestrol | Epimestrol may decrease the anticoagulant activities of Astaxanthin. |
| Moxestrol | Moxestrol may decrease the anticoagulant activities of Astaxanthin. |
| Estradiol acetate | Estradiol acetate may decrease the anticoagulant activities of Astaxanthin. |
| Estradiol benzoate | Estradiol benzoate may decrease the anticoagulant activities of Astaxanthin. |
| Estradiol cypionate | Estradiol cypionate may decrease the anticoagulant activities of Astaxanthin. |
| Estradiol valerate | Estradiol valerate may decrease the anticoagulant activities of Astaxanthin. |
| Biochanin A | Biochanin A may decrease the anticoagulant activities of Astaxanthin. |
| Formononetin | Formononetin may decrease the anticoagulant activities of Astaxanthin. |
| Estriol | Estriol may decrease the anticoagulant activities of Astaxanthin. |
| Icosapent | The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Astaxanthin. |
| Mesalazine | The risk or severity of bleeding can be increased when Mesalazine is combined with Astaxanthin. |
| Indomethacin | The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Astaxanthin. |
| Nabumetone | The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Astaxanthin. |
| Ketorolac | The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Astaxanthin. |
| Tenoxicam | The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Astaxanthin. |
| Celecoxib | The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Astaxanthin. |
| Tolmetin | The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Astaxanthin. |
| Rofecoxib | The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Astaxanthin. |
| Piroxicam | The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Astaxanthin. |
| Fenoprofen | The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Astaxanthin. |
| Valdecoxib | The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Astaxanthin. |
| Diclofenac | The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Astaxanthin. |
| Sulindac | The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Astaxanthin. |
| Flurbiprofen | The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Astaxanthin. |
| Etodolac | The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Astaxanthin. |
| Mefenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Astaxanthin. |
| Naproxen | The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Astaxanthin. |
| Sulfasalazine | The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Astaxanthin. |
| Phenylbutazone | The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Astaxanthin. |
| Meloxicam | The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Astaxanthin. |
| Carprofen | The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Astaxanthin. |
| Diflunisal | The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Astaxanthin. |
| Salicylic acid | The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Astaxanthin. |
| Meclofenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Astaxanthin. |
| Oxaprozin | The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Astaxanthin. |
| Ketoprofen | The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Astaxanthin. |
| Balsalazide | The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Astaxanthin. |
| Olsalazine | The risk or severity of bleeding can be increased when Olsalazine is combined with Astaxanthin. |
| Lumiracoxib | The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Astaxanthin. |
| Magnesium salicylate | The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Astaxanthin. |
| Salsalate | The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Astaxanthin. |
| Choline magnesium trisalicylate | The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Astaxanthin. |
| Antrafenine | The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Astaxanthin. |
| Aminophenazone | The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Astaxanthin. |
| Antipyrine | The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Astaxanthin. |
| Tiaprofenic acid | The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Astaxanthin. |
| Etoricoxib | The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Astaxanthin. |
| Taxifolin | The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Astaxanthin. |
| Oxyphenbutazone | The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Astaxanthin. |
| Licofelone | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Astaxanthin. |